The present disclosure relates to methods of treating certain CNS disorders. The present disclosure also relates to biomarkers for monitoring or predicting the efficacy of a treatment for a CNS disorder by lurasidone, or a pharmaceutically acceptable salt, solvate, clathrate or stereoisomer thereof.
